Active, not recruitingPhase 3NCT05089084
Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)
Studying Familial apolipoprotein C-II deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Arrowhead Pharmaceuticals
- Intervention
- Plozasiran(drug)
- Enrollment
- 75 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (30)
- Clinical Site 1, Boca Raton, Florida, United States
- Clinical Site 2, Suwanee, Georgia, United States
- Clinical Site 3, Indianapolis, Indiana, United States
- Clinical Site 4, Elkridge, Maryland, United States
- Clinical Site 5, St Louis, Missouri, United States
- Clinical Site 7, New York, New York, United States
- Clinical Site 6, New York, New York, United States
- Clinical Site 8, Austin, Texas, United States
- Clinical Site 9, Norfolk, Virginia, United States
- Clinical Site 10, Córdoba, Argentina
- Clinical Site 11, Formosa, Argentina
- Clinical Site 14, Camperdown, New South Wales, Australia
- Clinical Site 15, St Leonards, New South Wales, Australia
- Clinical Site 16, Melbourne, Victoria, Australia
- Clinical Site 12, Melbourne, Australia
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05089084 on ClinicalTrials.gov